ORIC Pharmaceuticals’ (ORIC) “Overweight” Rating Reiterated at Cantor Fitzgerald

Cantor Fitzgerald restated their overweight rating on shares of ORIC Pharmaceuticals (NASDAQ:ORICFree Report) in a research note published on Thursday, Benzinga reports.

Other research analysts have also issued research reports about the stock. JPMorgan Chase & Co. lowered their price objective on shares of ORIC Pharmaceuticals from $19.00 to $18.00 and set an overweight rating for the company in a research note on Wednesday, March 27th. Citigroup cut their price objective on shares of ORIC Pharmaceuticals from $15.00 to $14.00 and set a buy rating on the stock in a report on Tuesday, May 7th. HC Wainwright raised their price objective on shares of ORIC Pharmaceuticals from $15.00 to $21.00 and gave the stock a buy rating in a report on Thursday, March 21st. Finally, Wedbush raised their price objective on shares of ORIC Pharmaceuticals from $12.00 to $20.00 and gave the stock an outperform rating in a report on Friday, March 1st. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of Buy and a consensus price target of $20.00.

Check Out Our Latest Research Report on ORIC Pharmaceuticals

ORIC Pharmaceuticals Stock Up 3.1 %

Shares of NASDAQ ORIC opened at $7.23 on Thursday. The firm has a 50-day simple moving average of $8.71 and a 200-day simple moving average of $10.31. The stock has a market capitalization of $487.45 million, a price-to-earnings ratio of -4.02 and a beta of 1.18. ORIC Pharmaceuticals has a 52 week low of $5.27 and a 52 week high of $16.65.

ORIC Pharmaceuticals (NASDAQ:ORICGet Free Report) last announced its quarterly earnings data on Monday, May 6th. The company reported ($0.37) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.44) by $0.07. As a group, equities research analysts expect that ORIC Pharmaceuticals will post -1.68 EPS for the current year.

Hedge Funds Weigh In On ORIC Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the company. AJOVista LLC acquired a new position in shares of ORIC Pharmaceuticals during the 4th quarter worth $40,000. China Universal Asset Management Co. Ltd. acquired a new position in ORIC Pharmaceuticals in the 4th quarter valued at about $58,000. Strs Ohio acquired a new position in ORIC Pharmaceuticals in the 4th quarter valued at about $72,000. Tower Research Capital LLC TRC raised its stake in ORIC Pharmaceuticals by 19.6% in the 4th quarter. Tower Research Capital LLC TRC now owns 9,255 shares of the company’s stock valued at $85,000 after purchasing an additional 1,517 shares during the last quarter. Finally, ProShare Advisors LLC acquired a new position in ORIC Pharmaceuticals in the 1st quarter valued at about $161,000. 95.05% of the stock is currently owned by hedge funds and other institutional investors.

About ORIC Pharmaceuticals

(Get Free Report)

ORIC Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor, currently under Phase 1b study, which is designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer, currently under Phase 1b study; and ORIC-533, an orally bioavailable small molecule inhibitor of CD73, currently under Phase 1b study, being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens.

Featured Articles

Analyst Recommendations for ORIC Pharmaceuticals (NASDAQ:ORIC)

Receive News & Ratings for ORIC Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ORIC Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.